

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 FEBRUARY 2023

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

| <u>Item</u> | <u>PBAC Advice</u> |
|----------------------------|---|
| Exenatide | <p>The sponsor requested the delisting of Byetta[®] (exenatide) from the Pharmaceutical Benefits Scheme (PBS).</p> <p>The PBAC noted the low utilisation, available clinical alternatives and sponsor's intent to discontinue supply of the product. The PBAC advised the delisting of this drug would not result in an unmet clinical need.</p> |
| Ledipasvir with sofosbuvir | <p>The sponsor requested the delisting of Harvoni[®] (ledipasvir with sofosbuvir) from the PBS.</p> <p>The PBAC noted the low utilisation, current role in therapy and clinical alternatives. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p> |

Vanessa McMahon
Director
PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
13 January 2022